Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Verify the report on the official SGS website with ID " QIP-ASI254848 "
Figure 1: Cumulative Distribution of Response for Belly Appearance Distress Extension Phase (Weeks 26-52) In the double-blind Extension Phase, patients on a 2 mg dose of EGRIFTA (1 mg/vial formulation) completing the 26-week Main Phase were re-randomized to receive a 2 mg dose of EGRIFTA (1 mg/ vial formulation) or placebo
Thymosin Alpha-1 is often studied in relation to immune system support, chronic infection models, and immune deficiency research
The effectiveness of treatment will be analysed by examining the therapeutic success achieved in each arm at 8, 26 and 52 weeks, determining the 95% confidence interval for the percentage of patients in each treatment arm whose serum vitamin B12 concentrations become normalised
US$ 28.67
US$ 25.27
US$ 26.74
